International journal of cardiology · 2025
Impact of centre experience on complete clinical and haemodynamic response after alcohol septal ablation for hypertrophic obstructive cardiomyopathy.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Veselka Josef, Liebregts Max, Cooper Robert, Faber Lothar, Januska Jaroslav, Krejci Jan, Dabrowski Maciej, Hansen Peter Riis, Seggewiss Hubert, Ten Berg Jurriën, Stables Rodney Hilton, Dusek Ladislav, Tesarkova Klara Hulikova
Аннотация
BACKGROUND: Alcohol septal ablation (ASA) is an established therapy for symptomatic hypertrophic obstructive cardiomyopathy (HOCM) in patients unresponsive to medical treatment. However, comprehensive assessment of ASA outcomes remains challenging. This study aimed to evaluate the impact of institutional experience and patient characteristics on achieving complete clinical and haemodynamic response (CCHR), a novel composite outcome integrating long-term symptomatic, haemodynamic, safety, and major clinical endpoints, including survival and resuscitation.
METHODS: We retrospectively analysed 1206 symptomatic HOCM patients undergoing first-time ASA between 1996 and 2023 in seven European centres. CCHR was defined as residual left ventricular outflow tract (LVOT) gradient <30 mmHg, NYHA class I/II, absence of new permanent pacemaker implantation, and absence of major adverse cardiovascular events at last follow-up.
RESULTS: After a median follow-up of 4.9 (IQR 2.0-7.0) years, CCHR was achieved in 59 % of patients, with inter-centre variability ranging from 21.4 % to 69.3 %. Centres with higher procedural volumes showed significantly better outcomes. Patients treated within the first 50 procedures at a centre had significantly lower odds of achieving CCHR (OR 0.49; 95 % CI 0.34-0.71; p < 0.001). Younger age, lower baseline LVOT gradient, and higher baseline ejection fraction were independent predictors of success.
CONCLUSIONS: CCHR, integrating both haemodynamic and hard clinical outcomes, was achieved in the majority of ASA-treated HOCM patients. Institutional experience and patient selection emerged as key determinants of success. These findings support centralisation of ASA in high-volume centres and may inform patient-tailored therapeutic strategies.
METHODS: We retrospectively analysed 1206 symptomatic HOCM patients undergoing first-time ASA between 1996 and 2023 in seven European centres. CCHR was defined as residual left ventricular outflow tract (LVOT) gradient <30 mmHg, NYHA class I/II, absence of new permanent pacemaker implantation, and absence of major adverse cardiovascular events at last follow-up.
RESULTS: After a median follow-up of 4.9 (IQR 2.0-7.0) years, CCHR was achieved in 59 % of patients, with inter-centre variability ranging from 21.4 % to 69.3 %. Centres with higher procedural volumes showed significantly better outcomes. Patients treated within the first 50 procedures at a centre had significantly lower odds of achieving CCHR (OR 0.49; 95 % CI 0.34-0.71; p < 0.001). Younger age, lower baseline LVOT gradient, and higher baseline ejection fraction were independent predictors of success.
CONCLUSIONS: CCHR, integrating both haemodynamic and hard clinical outcomes, was achieved in the majority of ASA-treated HOCM patients. Institutional experience and patient selection emerged as key determinants of success. These findings support centralisation of ASA in high-volume centres and may inform patient-tailored therapeutic strategies.